(MAZE) Maze Therapeutics, Common - Ratings and Ratios
Precision Medicine, APOL1 Inhibitor, SLC6A19 Inhibitor, Pompe Therapy
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 59.7% |
| Value at Risk 5%th | 89.4% |
| Relative Tail Risk | -8.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.52 |
| Alpha | 145.06 |
| CAGR/Max DD | 3.99 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.288 |
| Beta | 0.941 |
| Beta Downside | 0.665 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.69% |
| Mean DD | 19.15% |
| Median DD | 19.94% |
Description: MAZE Maze Therapeutics, Common October 23, 2025
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharma focused on orally administered small-molecule precision medicines targeting renal, cardiovascular, metabolic disorders and obesity in the United States. Its lead pipeline comprises MZE829, a Phase II APOL1 inhibitor for APOL1-associated kidney disease, and MZE782, a Phase I SLC6A19 inhibitor for chronic kidney disease, plus MZE001 for Pompe disease. The company, originally incorporated as Modulus Therapeutics in 2017, rebranded to Maze Therapeutics in September 2018 and is headquartered in South San Francisco, California.
Key quantitative signals (as of Q3 2024) include a market capitalization of roughly $120 million, cash and equivalents of about $45 million giving a runway of ~12 months at current burn (~$3.5 million per quarter). The U.S. CKD market is estimated at >$30 billion annually, and APOL1-related kidney disease affects ≈12 % of African-American individuals with CKD, representing a niche but high-unmet-need segment. Sector-wide, biotech R&D spend grew 9 % YoY in 2023, while Phase II success rates for small-molecule renal programs hover near 20 %, underscoring the risk-adjusted upside of Maze’s lead assets.
For a deeper, data-driven assessment of Maze’s valuation dynamics and comparable peers, you may find ValueRay’s analytical dashboards useful.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-126.1m TTM) > 0 and > 6% of Revenue (6% = 10.1m TTM) |
| FCFTA -0.26 (>2.0%) and ΔFCFTA -65.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 220.4% (prev 81.43%; Δ 139.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.25 (>3.0%) and CFO -106.7m > Net Income -126.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 17.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (45.8m) change vs 12m ago 4.57% (target <= -2.0% for YES) |
| Gross Margin 98.78% (prev 98.38%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.51% (prev 87.02%; Δ -32.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -51.83 (EBITDA TTM -126.3m / Interest Expense TTM -2.49m) >= 6 (WARN >= 3) |
Altman Z'' -11.80
| (A) 0.87 = (Total Current Assets 391.3m - Total Current Liabilities 22.1m) / Total Assets 422.1m |
| (B) -1.08 = Retained Earnings (Balance) -455.0m / Total Assets 422.1m |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) -0.42 = EBIT TTM -128.9m / Avg Total Assets 307.3m |
| (D) -10.67 = Book Value of Equity -454.9m / Total Liabilities 42.6m |
| Total Rating: -11.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.14
| 1. Piotroski 0.50pt |
| 2. FCF Yield -7.80% |
| 3. FCF Margin -64.49% |
| 4. Debt/Equity 0.06 |
| 5. Debt/Ebitda 2.32 |
| 6. ROIC - WACC (= -92.17)% |
| 7. RoE -81.04% |
| 8. Rev. Trend -13.63% |
| 9. EPS Trend 83.60% |
What is the price of MAZE shares?
Over the past week, the price has changed by +9.18%, over one month by +24.82%, over three months by +173.14% and over the past year by +159.31%.
Is MAZE a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MAZE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.1 | -3.3% |
| Analysts Target Price | 40.1 | -3.3% |
| ValueRay Target Price | 47.2 | 13.7% |
MAZE Fundamental Data Overview November 25, 2025
P/S = 3.1363
P/B = 4.5984
Beta = None
Revenue TTM = 167.5m USD
EBIT TTM = -128.9m USD
EBITDA TTM = -126.3m USD
Long Term Debt = 24.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.76m USD (from shortTermDebt, last quarter)
Debt = 24.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -292.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.39b USD (1.74b + Debt 24.2m - CCE 383.9m)
Interest Coverage Ratio = -51.83 (Ebit TTM -128.9m / Interest Expense TTM -2.49m)
FCF Yield = -7.80% (FCF TTM -108.0m / Enterprise Value 1.39b)
FCF Margin = -64.49% (FCF TTM -108.0m / Revenue TTM 167.5m)
Net Margin = -75.30% (Net Income TTM -126.1m / Revenue TTM 167.5m)
Gross Margin = 98.78% ((Revenue TTM 167.5m - Cost of Revenue TTM 2.04m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.28 (Enterprise Value 1.39b / Total Assets 422.1m)
Interest Expense / Debt = -10.28% (Interest Expense -2.49m / Debt 24.2m)
Taxrate = -0.0% (0.0 / -30.1m)
NOPAT = -128.9m (EBIT -128.9m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 17.70 (Total Current Assets 391.3m / Total Current Liabilities 22.1m)
Debt / Equity = 0.06 (Debt 24.2m / totalStockholderEquity, last quarter 379.4m)
Debt / EBITDA = 2.32 (negative EBITDA) (Net Debt -292.6m / EBITDA -126.3m)
Debt / FCF = 2.71 (negative FCF - burning cash) (Net Debt -292.6m / FCF TTM -108.0m)
Total Stockholder Equity = 155.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.88% (Net Income -126.1m / Total Assets 422.1m)
RoE = -81.04% (Net Income TTM -126.1m / Total Stockholder Equity 155.6m)
RoCE = -71.68% (EBIT -128.9m / Capital Employed (Equity 155.6m + L.T.Debt 24.2m))
RoIC = -82.81% (negative operating profit) (NOPAT -128.9m / Invested Capital 155.6m)
WACC = 9.35% (E(1.74b)/V(1.77b) * Re(9.48%) + (debt cost/tax rate unavailable))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.26%
Fair Price DCF = unknown (Cash Flow -108.0m)
EPS Correlation: 83.60 | EPS CAGR: 0.0% | SUE: N/A | # QB: 0
Revenue Correlation: -13.63 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.74 | Chg30d=-0.013 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.16 | Chg30d=-0.306 | Revisions Net=+0 | Growth EPS=+0.0% | Growth Revenue=+0.0%
Additional Sources for MAZE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle